My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.930 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.930
Bid (Size) 1.930 (7)
Ask (Size) 2.200 (10)
Prev. Close 1.930
Today's Range 1.930 - 1.930
52wk Range 0.6600 - 2.999
Shares Outstanding 60,705,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss
Caribou Biosciences reports Q2 2025 earnings with revenue beating estimates at $2.67M but a wider EPS loss of -$0.58. Clinical updates expected in H2 2025. 
Via Chartmill

Performance

YTD
+14.9%
+14.9%
1 Month
-3.5%
-3.5%
3 Month
+43.0%
+43.0%
6 Month
+95.2%
+95.2%
1 Year
+2.1%
+2.1%

More News

Read More
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
Via Benzinga
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
From Faruqi & Faruqi LLP
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, BioAge, and Transocean and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Caribou, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
From Faruqi & Faruqi LLP
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire

Frequently Asked Questions

Is Caribou Biosciences, Inc. - Common Stock publicly traded?
Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Caribou Biosciences, Inc. - Common Stock trade on?
Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?
The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market
What is the current price of Caribou Biosciences, Inc. - Common Stock?
The current price of Caribou Biosciences, Inc. - Common Stock is 1.930
When was Caribou Biosciences, Inc. - Common Stock last traded?
The last trade of Caribou Biosciences, Inc. - Common Stock was at 09/25/25 04:00 PM ET
What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?
The market capitalization of Caribou Biosciences, Inc. - Common Stock is 117.16M
How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?
Caribou Biosciences, Inc. - Common Stock has 117M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.